RBC Capital lowered the firm’s price target on Bio-Rad (BIO) to $447 from $477 and keeps an Outperform rating on the shares. The company reported a slight miss for Q4, with guidance coming in below consensus estimates on the top and bottom line, though based on peers’ results thus far, the low-single-digit top-line guide is not a major surprise, the analyst tells investors in a research note. RBC adds however that the lack of meaningful margin expansion by Bio-Rad was still surprising.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue